Pamela L. Valentino

Pamela L. Valentino

Auto-generated profile, based on publicly available information

Pamela L. Valentino

Division of Gastroenterology and Hepatology, Department of Pediatrics, Seattle Children's Hospital, University of Washington School, WA; and

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 October 2022 in Hepatology
Verified
Journal Article
Open access
SVShannon M. Vandriel
Shannon M. Vandriel
LLLi‐Ting Li
Li‐Ting Li
HSHuiyu She
Huiyu She
JWJian‐She Wang
Jian‐She Wang
MGMelissa A. Gilbert
Melissa A. Gilbert
BKBinita M. Kamath
Binita M. Kamath
Background and Aims: Alagille syndrome (ALGS) is a multisystem disorder, characterized by cholestasis. Existing outcome data are largely derived from tertiary centers, and real‐world data are lacking. This study aimed to elucidate the natural history of liver disease in a contemporary, international cohort of children with ALGS. Approach and Results: This was a multicenter retrospective study of children with a clinically and/or genetically confirmed ALGS diagnosis, born between January 1997 and August 2019. Native liver survival (NLS) and event‐free survival rates were assessed. Cox models were constructed to identify early biochemical predictors of clinically evident portal hypertension (CEPH) and NLS. In total, 1433 children (57% male) from 67 centers in 29 countries were included. The 10 and 18‐year NLS rates were 54.4% and 40.3%. By 10 and 18 years, 51.5% and 66.0% of children with ALGS experienced ≥1 adverse liver‐related event (CEPH, transplant, or death). Children (>6 and ≤12 months) with median total bilirubin (TB) levels between ≥5.0 and <10.0 mg/dl had a 4.1‐fold (95% confidence interval [CI], 1.6–10.8), and those ≥10.0 mg/dl had an 8.0‐fold (95% CI, 3.4–18.4) increased risk of developing CEPH compared with those <5.0 mg/dl. Median TB levels between ≥5.0 and 10.0 mg/dl were associated with a 4.8 (95% CI, 2.4–9.7) and 15.6 (95% CI, 8.7–28.2) increased risk of transplantation relative to <5.0 mg/dl. Median TB <5.0 mg/dl were associated with higher NLS rates relative to ≥5.0 mg/dl, with 79% reaching adulthood with native liver (p < 0.001). Conclusions: In this large international cohort of ALGS, only 40.3% of children reach adulthood with their native liver. A TB <5.0 mg/dl between 6 and 12 months of age is associated with better hepatic outcomes. These thresholds provide clinicians with an objective tool to assist with clinical decision‐making and in the evaluation of therapies.

17 March 2021 in Hepatology
Verified
Journal Article
Closed access
MDMark R. Deneau
Mark R. Deneau
CMCara Mack
Cara Mack
DMDouglas Mogul
Douglas Mogul
EPEmily R. Perito
Emily R. Perito
PVPamela L. Valentino
Pamela L. Valentino
SGStephen L. Guthery
Stephen L. Guthery

1 December 2016 in Journal of Pediatric Gastroenterology and Nutrition
Verified
Journal Article
Closed access
PVPamela L. Valentino
Pamela L. Valentino
SWShanna Wiggins
Shanna Wiggins
SHSarah Harney
Sarah Harney
RRRoshan Raza
Roshan Raza
CLChristine K. Lee
Christine K. Lee
MJMaureen M. Jonas
Maureen M. Jonas

19 December 2020 in Hepatology
Verified
Journal Article
Closed access
MDMark R. Deneau
Mark R. Deneau
CMCara Mack
Cara Mack
EPEmily R. Perito
Emily R. Perito
ARAmanda Ricciuto
Amanda Ricciuto
PVPamela L. Valentino
Pamela L. Valentino
SGStephen L. Guthery
Stephen L. Guthery

21 March 2022 in Hepatology Communications
Verified
Journal Article
Open access
KYKangning Yao
Kangning Yao
ETElena Tarabra
Elena Tarabra
DSDaniela Sia
Daniela Sia
RMRaffaella Morotti
Raffaella Morotti
RFRima Fawaz
Rima Fawaz
DYDean Yimlamai
Dean Yimlamai
Nonalcoholic fatty liver disease (NAFLD) is the most common type of chronic liver disease in children. The mechanisms that drive NAFLD disease progression in this specific patient population remain poorly defined. In this study, we obtained liver biopsy samples from a multiethnic cohort of pediatric patients with NAFLD (n = 52, mean age = 13.6 years) and healthy liver controls (n = 5). We analyzed transcriptomic changes associated with NAFLD stages using high‐throughput RNA sequencing. Unsupervised clustering as well as pairwise transcriptome comparison distinguished NAFLD from healthy livers. We identified perturbations in pathways including calcium and insulin/glucose signaling occurring early in NAFLD disease, before the presence of histopathologic evidence of advanced disease. Transcriptomic comparisons identified a 25‐gene signature associated with the degree of liver fibrosis. We also identified expression of the insulin‐like growth factor binding protein (IGFBP) gene family (1/2/3/7) as correlating with disease stages, and it has the potential to be used as a peripheral biomarker in NAFLD. Comparing our data set with publicly available adult and adolescent transcriptomic data, we identified similarities and differences in pathway enrichment and gene‐expression profiles between adult and pediatric patients with NAFLD. Regulation of genes including interleukin‐32, IGFBP1, IGFBP2, and IGFBP7 was consistently found in both NAFLD populations, whereas IGFBP3 was specific to pediatric NAFLD. Conclusion: This paper expands our knowledge on the molecular mechanisms underlying pediatric NAFLD. It identifies potential biomarkers and directs us toward new therapies in this population.

9 September 2021 in Hepatology
Verified
Journal Article
Closed access
MMMercedes Martinez
Mercedes Martinez
EPEmily R. Perito
Emily R. Perito
PVPamela Valentino
Pamela Valentino
CMCara L Mack
Cara L Mack
MAMadeleine Aumar
Madeleine Aumar
MDMark R. Deneau
Mark R. Deneau